Aims: Enteropeptidase is a serine protease localized on the duodenal brush border that catalyzes the conversion of inactive trypsinogen into active trypsin, thereby regulating protein breakdown in the gut. We evaluated the effects of SCO-792, a novel enteropeptidase inhibitor, in mice. Conclusions: SCO-792 inhibited enteropeptidase in vivo, reduced food intake, decreased body weight, increased insulin sensitivity, improved glucose and lipid control, and ameliorated liver parameters in mouse models with obesity and/or diabetes. SCO-792 may exhibit similar effects in patients.
| INTRODUCTION
Obesity is an abnormal condition with excessive body fat accumulation, mostly the result of a chronic imbalance between energy intake and energy expenditure; it is a primary factor in all obesity-related complications such as type 2 diabetes, dyslipidaemia and cardiovascular diseases. [1] [2] [3] [4] Although individual and genetic factors influence its onset and severity, the major causative factor for obesity is excessive calorie intake from the three macronutrients, fat, carbohydrate and protein, which provide nine, four and four calories per gram, respectively. 5, 6 From the therapeutic perspective, researchers have developed inhibitors to block gut nutrient absorption, thereby inducing treatment effects for various diseases. For instance, pancreatic and intestinal lipase inhibitors, which inhibit fat breakdown in the gut, were developed and used clinically as a potential treatment for dyslipidaemia and obesity. 7 Similarly, alpha-glucosidase inhibitors are well-known antidiabetic drugs that inhibit the digestion of carbohydrates, such as starch and sugar, thereby blocking glucose uptake in the gut. 8 These approaches are reasonable for patients who over ingest foods with high fat and/or high carbohydrate content, but the mechanism-driven gastrointestinal side-effects, including oily spotting, fecal incontinence and diarrhea, limit patient compliance. 9, 10 Although proteins contain the same number of calories as carbohydrates, drugs that inhibit dietary protein absorption, unlike carbohydrate and fat absorption, have not been developed for treating metabolic diseases.
Enteropeptidase (enterokinase, EC3.4.21.9) is a transmembrane serine protease, localized at the brush border of the duodenal and jejunal mucosa, which is involved in food digestion in mammals. [11] [12] [13] Enteropeptidase converts inactive trypsinogen into its active form, trypsin, resulting in the subsequent activation of digestive enzyme precursors produced in the pancreas (eg, chymotrypsinogen, proelastase and procarboxypeptidases A and B). [11] [12] [13] These activated enzymes facilitate protein breakdown, resulting in amino acid absorption in the gut. [11] [12] [13] Notably, a congenital enteropeptidase deficiency is known to be associated with a lean phenotype in humans. 14, 15 In addition, it has been reported that OBE-2008, an enteropeptidase inhibitor, inhibited body weight gain during a 2-month study involving the growth phase in DIO mice. 15 This suggests that enteropeptidase inhibition may constitute a novel strategy to improve body weight control in obesity. However, the pharmacological effects of enteropeptidase inhibition on food intake, body weight and metabolic parameters are not well characterized. SCO-792 is a novel, orally available enteropeptidase inhibitor that is currently undergoing evaluation in clinical trials. 16 It is reported to show potent inhibitory activity against human enteropeptidase when tested in vitro (complete enteropeptidase inhibition at 3.3 μM SCO-792 in vitro). 16 Here, we evaluated the therapeutic effects of SCO-792 on obesity and diabetes in mouse models. First, we evaluated the plasma biomarker changes induced by SCO-792. Next, the body weight lowering effects of SCO-792 were evaluated in diet-induced obese (DIO) mice.
The metabolic effects of SCO-792 were evaluated in genetically obese and diabetic mice. Additional experiments were performed to reveal effects of SCO-792 on FGF21 levels and whole body insulin sensitivity, and to elucidate a role of essential amino acid intake on SCO-792-induced food intake and body weight reduction in mouse models.
| MATERIALS AND METHODS

| Chemicals
All reagents were purchased from FUJIFILM Wako Pure Chemical Corporation (Osaka, Japan) or Sigma-Aldrich (Tokyo, Japan) unless otherwise indicated. SCO-792 and pioglitazone were synthesized by Takeda Pharmaceutical Company Limited (Tokyo, Japan). Sibutramine was purchased from Enzo Life Sciences, Inc (Farmingdale, New York).
Doses of compounds are expressed in free base form.
| Animals
All animals were housed in a room with controlled temperature 
| Repeated dosing in DIO mice
The DIO model was established by using an HFD (D12079B) from 5 weeks of age until initiation of the study. Male DIO mice, 46 weeks of age, with a baseline body weight of 49.3 ± 2.9 g, were divided into four groups (n = 6 for vehicle and SCO-792; n = 4 for sibutramine) 2.6 | Short-term study for measuring fibroblast growth factor 21 (FGF21) in DIO mice
The DIO model was established by using an HFD (D12079B) from as the ratio of the labelled glucose infusion rate (dpm/kg/min) to plasma glucose-specific activity (dpm/mg). Hepatic glucose production was calculated by subtracting the glucose infusion rate from the glucose disposal rate.
| Evaluation of amino acid supplementation in C57BL/6J mice
Male C57/BL 6J mice, 9 weeks of age, with a baseline body weight of 23.8 ± 0.9 g, were randomized into four groups (n = 5) based on food intake and body weight. Mice received a powder diet (CE-2) only or a diet containing 0.01% (w/w) SCO-792 in the presence of essential amino acids for 8 days. Nine essential amino acids (histidine, isoleucine, leucine, lysine, methionine, phenylalanine, threonine, tryptophan, valine) were mixed at 0.92% (w/w) each into a normal chow diet.
Food intake and body weight were measured at the time points indicated in the Results section and in the associated Figures.
| Statistical analysis
Statistical significance was first analysed using Bartlett's test for homogeneity of variances, followed by the Williams' test (P > .05) and the Shirley-Williams test (P ≤ .05) for dose-dependent studies and the Dunnett's test (P > .05) and the Steel test (P ≤ .05) for multiple comparisons. Alternatively, statistical significance was analysed using the F test for homogeneity of variances, followed by the Student's t-test (P > .2) or the Aspin-Welch test (P ≤ .2). The Williams' and ShirleyWilliams tests were conducted using a one-tailed significance level of 2.5% (0.025). Other tests were conducted using a two-tailed significance level of 5% (0.05). All data are presented as mean ± standard deviation (SD).
Methods for biochemical measurement, measurement of hepatic triglyceride and total cholesterol contents, BCAA measurement and measurement of fecal protein content are included in the Appendix S1.
3 | RESULTS
| SCO-792 was an in vivo efficacious enteropeptidase inhibitor
Given that SCO-792 is a potent inhibitor against enteropeptidase 16 and that enteropeptidase activity, expressed exclusively in the duode- 
| SCO-792 improved obesity-related parameters in DIO mice
To evaluate the anti-obesity potential of enteropeptidase inhibition, SCO-792 was orally administered to DIO mice once-daily for 4 weeks.
As shown in Figure 2A , SCO-792 dose-dependently increased fecal protein levels. The average protein-derived calorie loss to the feces against total caloric intake was 0.6% (vehicle) 
| SCO-792 increased FGF21 levels in DIO mice
To evaluate the mechanism by which SCO-792 continuously decreases body weight, FGF21 levels, which reportedly increase 19, 20 were compared in SCO-792-treated DIO mice and pair-fed DIO mice. As shown in Figure 3A ,B, the SCO-792-treated and pair-fed groups show similar levels of food intake and body weight reduction in a 3-day study. At the end of the study, Fgf21 mRNA in liver and plasma FGF21 levels were increased in SCO-792-treated DIO mice, whereas these increases were not observed in pair-fed DIO mice ( Figure 3C,D) .
| SCO-792 improved disease status of diabetes and obesity in ob/ob mice
To evaluate the effect of sustained administration of SCO-792 on diabetic and obesity parameters, ob/ob mice were fed with a diet con- 
| SCO-792 improved insulin sensitivity in muscles
To test whether SCO-792 interferes with insulin action in ob/ob mice, hyperinsulinaemic-euglycaemic clamps were performed after 6 days of treatment, followed by overnight fasting. Metabolic analyses confirmed reductions in food intake, body weight, plasma glucose and plasma insulin in SCO-792-treated ob/ob mice immediately prior to a hyperinsulinaemic-euglycaemic clamp study ( Figure 5A-D) .
A clamp study ( Figure 5E ) revealed that ob/ob mice treated with SCO-792 required a higher glucose infusion rate to maintain euglycaemia as compared to mice that received vehicle ( Figure 5F -H). Hepatic glucose production during the clamp appeared to be similar between SCO-792-treated mice and those that received vehicle ( Figure 5I ). The glucose disposal rate was increased in SCO-792-treated ob/ob mice ( Figure 5J ). Glucose uptake, measured by 
| DISCUSSION
Enteropeptidase is a key enzyme that regulates protein breakdown in the gut. In this study, we evaluated the effects of SCO-792, a novel and highly effective enteropeptidase inhibitor, in mouse models. As expected, SCO-792 was demonstrated to inhibit protein breakdown in the gut. Of note, administration of SCO-792 resulted in inhibition of food intake and reduction in body weight in obese mouse models.
It also markedly improved abnormal metabolic parameters, including glucose, lipid and liver parameters, in obese/diabetic mice. Studies have also revealed that SCO-792 increased FGF21 levels in obese mice and increased muscular insulin sensitivity in obese/diabetic mice.
An amino acid supplementation of the diet partially reversed the effect of SCO-792, suggesting the role of enteropeptidase in control of metabolism and body weight. Thus, we propose the SCO-792-mediated inhibition of enteropeptidase as a novel treatment option for diabetes and obesity.
In a 4-week study of DIO mice, once-daily oral dosing of SCO-792 inhibited food intake, which was more evident in the early phase of the study, up to approximately 1 week, as compared to the rest of the study. Although the inhibition of food intake was attenuated at later stages, after approximately 1 week, body weight continued to decrease as a result of treatment with SCO-792. This suggests that a food intake inhibition-independent mechanism is likely to contribute to the SCO-792-induced decrease in body weight. Continued fecal exclusion of protein-derived calories may contribute, in part, to the sustained loss of body weight observed in mice. In a short-term study, treatment with SCO-792, but not pair-fed treatment, increased FGF21 levels in DIO mice. FGF21 reportedly increases energy expenditure in mice, thereby correcting obesity. 19, 20 Thus, SCO-792-mediated FGF21 elevation may have a role in body weight reduction. Gut GLP-1 and PYY are physiological hormones known to regulate satiety and body weight. 21 In the current study, plasma levels of total GLP-1 were slightly lower and plasma PYY remained unchanged in SCO-792-treated DIO mice. Thus, plasma GLP-1 and PYY are unlikely to play a significant role in body weight reduction in SCO-792-treated mice. Considering that SCO-792 alters protein conditions inside the gut, the microbiome may play a role in this F I G U R E 4 Effects of repeated administration of SCO-792 on metabolic parameters in ob/ob mice. ob/ob mice were treated with either SCO-792 (0.003%-0.01% added to the diet), pioglitazone (0.009% added to the diet) or vehicle alone for 2 weeks. A, Fecal protein at Day 7 (Days 6-7) and B, Day 14 (Days 13-14); C, food intake during the study period; D, total food intake; E, body weight during the study period; and F, body weight change at Day 14. Metabolic parameters were determined at the end of the study: G, plasma levels of glucose; H, glycosylated haemoglobin; I, insulin; J, triglycerides; K, total cholesterol; L, alanine transaminase; M, epididymal fat; N, subcutaneous fat; O, mesenteric fat; P, liver weight; Q, hepatic triglyceride content; and R hepatic total cholesterol content. Data are expressed as mean ± SD (n = 4-5 F I G U R E 5 Effects of repeated administration of SCO-792 on insulin sensitivity in ob/ob mice. ob/ob mice were treated with either SCO-792 (0.01% added to the diet) or vehicle alone for 6 days. A, Total food intake and B, body weight change; C, plasma glucose and D, insulin at end of study. E, After 6 days of dosing, mice were fasted overnight and hyperinsulinaemic-euglycaemic clamp was performed. F, Glucose infusion rate during hyperinsulinaemic-euglycaemic clamp. G, Plasma glucose levels maintained at c. 150 mg/dL during clamp procedure. H, Averaged glucose infusion rate; I, hepatic glucose production; and J, glucose disposal rate during steady state. Glucose uptake in K, muscle, L, liver and M, fat at end of clamp procedure. Data are expressed as mean ± SD (n = 14 and n = 16 for vehicle and SCO-792, respectively 
Effects of essential amino acid supplementation on SCO-792-induced food intake and body weight reduction in C57BL/6J mice. Food intake of A, normal diet group and B, essential amino acid-supplemented group were monitored throughout the study and C, total food intake was calculated. Body weight of D, normal diet group and E, essential amino acid-supplemented group were monitored throughout the study and F, percent change in body weight from initial values was determined. Data are expressed as mean ± SD (n = 4-5). a P ≤ .01 by Student's t-test. Abbreviations: EAA, essential amino acid; N.S., not significant
To the best of our knowledge, this report is the first to demonstrate that enteropeptidase inhibition acts to correct abnormally high glucose levels. In addition to its body weight-lowering effect, SCO- Although we demonstrated that treatment with SCO-792 was highly effective in improving diabetes and obesity disease states in mice, the key biological mechanisms/events by which SCO-792 induces these benefits remain unclear. Thus, further studies are essential to gain an understanding of how enteropeptidase inhibition results in the beneficial results observed in the current study.
In conclusion, the enteropeptidase inhibitor SCO-792 effectively improved insulin resistance and glucose control in a diabetic mouse model, while also showing substantial efficacy in lowering body weight in obese models. In addition, the favourable effect of treatment with SCO-792 in improving plasma and liver lipid profiles was demonstrated. These findings suggest that the inhibition of gut enteropeptidase activity with the concomitant protein breakdown modulation in the gut may offer a novel treatment option for obesity, diabetes and liver diseases.
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